ATS 2024 Final Program

Click on the session title to view the speakers

344

WEDNESDAY • MAY 22

813 Persistent Hypoxia in an Elderly Patient With a Patent Foramen Ovale (PFO): A Case Report of Platypnoea-Orthodeoxia Syndrome (POS) 814 A Rare Case of Klippel-Feil-Syndrome 815 Chilaiditi Syndrome: A Diagnostic Dilemma 816 A Case of Low Diffusing Capacity Due to Hepatopulmonary Syndrome in a Patient With a History of Cholangiocarcinoma 817 Sudden Onset Dyspnea and Hypoxemia in an 18-year-old Woman After Accidental Exposure to Bleach 818 Neurogenic Pulmonary Edema: A Case of the Disappearing Ground-Glass 819 Fibrosing Mediastinitis Resulting in Severe Pulmonary Hypertension 820 All That Tingles: A Case of Progressive Paralysis and Fatal Pulmonary Embolism 821 When Breathing Gets Bubbly: An Ehimsical Tale of Pneumomediastinum 822 Hereditary Hemochromatosis and a Year of Alcoholism: A Recipe for Failure BEHAVIORAL • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION D105 BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH 11:00 a.m. - 1:00 p.m. 401 Pulsatile Loading Affects Right Ventricular Function in Pulmonary Hypertension Due to Chronic Lung Disease 402 Impact of Baseline Pulmonary Vascular Resistance on Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension 403 A Potential Role for C5a in Pulmonary Arterial Hypertension and Response to Parenteral Prostacyclin Therapy San Diego Convention Center Room 25A-C (Upper Level) Poster Viewing 11:00-11:45 11:45-1:00 Discussion

404 CT Characteristics of COPD Patients With Impaired Diffusion Capacity; Implications for COPD-pulmonary Hypertension Phenotyping 405 From Highs to Lows: Impact of Continued Methamphetamine Usage on Pulmonary Arterial Hypertension 406 Metabolomic Assessment of Chronic PE at Rest and Peak Exercise Identifies Abnormalcomplex Lipid Metabolism 407 Physiological Mechanisms Behind Respiratory-induced Variations in Right Atrial Pressure 408 Invasive Cardiopulmonary Exercise Testing Phenotypes of Chronic Thromboembolic Pulmonary Vascular Disease 409 A Phase 3, 2-part, Open-label, Multicenter Study to Evaluate the Safety, and Efficacy of Liposomal Treprostinil Inhalation Suspension (l606) in Subjects With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lun 410 Clinical Improvements With Parenteral Induction Therapy in Intermediate-High Risk Patients With PAH: A Sub-Group Analysis of the EXPEDITE Study 411 SPECT ERNA and Cardiac Effort: The New Kids on the Block in Pulmonary Arterial Hypertension Monitoring 412 Exercise Hemodynamics and the Evolving Definition of Precapillary Pulmonary Hypertension 413 Selexipag for the Treatment of Schistosomiasis-associated Pulmonary Arterial Hypertension - The SELSCH Study 414 Transpulmonary Metabolomic Flux in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension During Exercise 415 Epicardial Adipose Tissue Is an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension 416 The Radiographic Spectrum of Small Pulmonary Vascular Abnormalities in Idiopathic Pulmonary Fibrosis 417 Applying the New Definition of Pulmonary Hypertension to Patients With Idiopathic Pulmonary Fibrosis on the Transplant Waitlist, A Registry Review

ATS 2024 • San Diego, CA